RD
Robert Driscoll Wedbush Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
29
Avg Return
Past Year
Past Year
23%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
83.3%
Neutral
12.5%
Negative
4.2%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Outperform
Reiterated
| $10 |
143%
upside
| 1 | -8.5% |
0
%
| 12 Mar ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $36 |
165%
upside
| 2 | +6.8% |
0
%
| 11 Mar ‘26 3 months ago |
|
|
|
Neutral
Downgraded
| $21.50 |
0%
downside
| 2 | +76% |
0
%
| 9 Mar ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $36 |
277%
upside
| 3 | +19% |
0
%
| 6 Mar ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $19 |
42%
downside
| 1 | +6.2% |
0
%
| 6 Mar ‘26 3 months ago |
|
|
|
Underperform
Initiated
| $7 |
25%
downside
| 1 | +20% |
0
%
| 26 Feb ‘26 3 months ago |
|
|
|
Neutral
Maintained
| $11 |
47%
upside
| 1 | – |
–
| 25 Feb ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $52 |
72%
upside
| 1 | +13% |
0
%
| 18 Feb ‘26 3 months ago |
|
|
|
Outperform
Maintained
| $53 |
86%
upside
| 2 | +30% |
0
%
| 13 Feb ‘26 4 months ago |
|
|
|
Outperform
Maintained
| $7 |
902%
upside
| 1 | +18% |
0
%
| 10 Feb ‘26 4 months ago |
|
|
|
Outperform
Maintained
| $19 |
112%
upside
| 3 | +31% |
0
%
| 4 Feb ‘26 4 months ago |
|
|
|
Outperform
Initiated
| $70 |
18%
upside
| 1 | +55% |
0
%
| 11 Dec ‘25 6 months ago |
|
|
|
Outperform
Maintained
| $80 |
50%
downside
| 4 | +28% |
0
%
| 6 Nov ‘25 7 months ago |
|
|
|
Outperform
Maintained
| $38 |
357%
upside
| 1 | -51% |
0
%
| 20 Oct ‘25 7 months ago |
|
|
|
Outperform
Initiated
| $27 |
48%
upside
| 1 | -10% |
0
%
| 14 Jul ‘25 11 months ago |
|